Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Head and Neck Cancer Clinical Trial

Official title:

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03212404
• Other study ID #: CK-301-101
• Status: Recruiting
• Phase: Phase 1
• Start date: September 20, 2017
• Est. completion date: December 2024

Study information

• Verified date: August 2023
• Source: Checkpoint Therapeutics, Inc.
• Contact: James Oliviero
• Phone: 001-212-574-2830
• Email: info[@]checkpointtx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

Description:

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301 (cosibelimab), a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months of visits with survival follow-up for select cohorts). Following the dose escalation portion of the study, additional evaluable subjects may be included in order to further characterize safety and efficacy at selected doses and/or in specific patient sub-groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 2024
• Est. primary completion date: November 18, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed written informed consent.

• Male or female subjects aged greater than or equal to 18 years.

• For NSCLC: Histologically or cytologically confirmed diagnosis of unresectable recurrent or metastatic non-small cell lung cancer.

• For CRC: Histologically confirmed diagnosis of recurrent or metastatic colorectal cancer assessed as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

• For EC: Histologically or cytologically confirmed advanced, recurrent or metastatic endometrial carcinoma.

• For cSCC: Histologically confirmed diagnosis of unresectable or metastatic cutaneous squamous cell carcinoma not amenable to local therapy.

• For SCLC: Histologically or cytologically confirmed diagnosis of unresectable small cell lung cancer.

• For MPM: Histologically or cytologically confirmed diagnosis of unresectable malignant pleural or peritoneal mesothelioma.

• For HNSCC: Histologically or cytologically confirmed diagnosis of recurrent or metastatic HNSCC (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).

• For MEL: Histologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy (excluding uveal or ocular melanoma).

• For MCC: Histologically confirmed diagnosis of metastatic Merkel cell carcinoma not amenable to local therapy.

• For RCC: Histologically confirmed diagnosis of renal cell carcinoma (with clear cell component) with advanced or metastatic disease that is not amenable to cure by surgery or other means.

• For UC: Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, urethra) not amenable to cure by surgery or other means.

• For HL: Histologically confirmed primary diagnosis of classical Hodgkin's lymphoma.

• For B-cell NHL: Histologically confirmed diagnosis of non-Hodgkin lymphoma.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months

• Must have at least one measurable lesion based on RECIST 1.1.

• Have provided a formalin fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated.

• Adequate hematological, hepatic and renal function as defined in the protocol.

• Effective contraception for both male and female subjects if the risk of conception exists.

• Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

• Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.

• Concurrent treatment with a non-permitted drug.

• History of severe hypersensitivity reactions to other monoclonal antibodies.

• Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, or localized prostate cancer.

• Chemotherapy, radioactive, biological cancer therapy, or tyrosine kinase inhibitor (TKI) therapy, within four weeks prior to the first dose of study drug, or who has not recovered to NCI CTCAE Grade 1 or better from the AEs due to cancer therapeutics administered more than four weeks earlier.

• Significant acute or chronic infections as defined in the protocol.

• Active or history of interstitial lung disease (ILD), or has had a history of pneumonitis that has required oral or IV steroids.

• Active or suspected autoimmune disease or a documented history of autoimmune disease.

• Known current drug or alcohol abuse.

• Underlying medical conditions that will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.

• Use of other investigational therapy within 28 days before study drug administration.

• Pregnant or breastfeeding.

• Uncontrolled or significant cardiovascular disease.

• Psychiatric illness or social situation that would preclude study compliance.

• Receipt of live, attenuated vaccine within 28 days prior to the first dose of study drug.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Merkel Cell
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Small Cell
• Classical Hodgkin Lymphoma
• Cutaneous Squamous Cell Carcinoma
• Endometrial Cancer
• Endometrial Neoplasms
• Head and Neck Cancer
• Lung Neoplasms
• Lymphoma
• Malignant Mesothelioma, Advanced
• Melanoma
• Merkel Cell Carcinoma
• Mesothelioma
• Mesothelioma, Malignant
• Non Hodgkin Lymphoma
• Renal Cell Carcinoma
• Urothelial Carcinoma

Intervention

Drug:
• CK-301 (cosibelimab)
CK-301 will be administered in periods of 28-day cycles.

Locations

Country	Name	City	State
Australia	Research Site	Benowa	Queensland
Australia	Research Site	Box Hill	Victoria
Australia	Research Site	Buderim	Queensland
Australia	Research Site	Greenslopes	Queensland
Australia	Research Site	Malvern	Victoria
Australia	Research Site	South Brisbane	Queensland
Australia	Research Site	Wollongong	New South Wales
Australia	Research Site	Woolloongabba	Queensland
France	Research Site	Besançon
France	Research Site	Bordeaux
France	Research Site	Grenoble
France	Research Site	Lyon
France	Research Site	Nice
New Zealand	Research Site	Christchurch
Poland	Research Site	Kraków
Poland	Research Site	Lódz
Poland	Research Site	Lublin
Poland	Research Site	Poznan
Poland	Research Site	Warsaw
Russian Federation	Research Site	Chelyabinsk
Russian Federation	Research Site	Kazan
Russian Federation	Research Site	Murmansk
Russian Federation	Research Site	Novosibirsk
Russian Federation	Research Site	Omsk
Russian Federation	Research Site	Saint Petersburg
Russian Federation	Research Site	Saint Petersburg
Russian Federation	Research Site	Tyumen
Russian Federation	Research Site	Volgograd
South Africa	Research Site	Cape Town
South Africa	Research Site	George
South Africa	Research Site	Port Elizabeth
South Africa	Research Site	Pretoria
South Africa	Research Site	Soweto
Spain	Research Site	Barcelona
Spain	Research Site	La Laguna
Spain	Research Site	Madrid
Spain	Research Site	Málaga
Spain	Research Site	Pamplona
Spain	Research Site	Sevilla
Spain	Research Site	Valencia
Thailand	Research Site	Bangkok
Thailand	Research Site	Bangkok
Thailand	Research Site	Chiang Mai
Thailand	Research Site	Hat Yai	Songkhla
Thailand	Research Site	Khon Kaen
Ukraine	Research Site	Chernivtsi
Ukraine	Research Site	Kharkiv
Ukraine	Research Site	Sumy

Sponsors (2)

Lead Sponsor	Collaborator
Checkpoint Therapeutics, Inc.	Novotech (Australia) Pty Limited

Countries where clinical trial is conducted

Australia,  France,  New Zealand,  Poland,  Russian Federation,  South Africa,  Spain,  Thailand,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Limiting Toxicity		Up to 4 weeks
Primary	Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version)		Screening through 4 weeks after study completion, an average of 6 months
Primary	Confirmed Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)		Part 2 Only: Average of 6 months
Secondary	Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)		Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
Secondary	Duration of Response (DoR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)		Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
Secondary	Objective response rate and duration of response (DOR) based on Modified RECIST 1.1 for immune based therapeutics		Part 2 Only: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
Secondary	Overall Survival (OS)		Part 2 Only: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
Secondary	Pharmacokinetic parameter: AUC (0-t) of CK-301		Baseline up to 12 weeks after study completion, an average of 6 months
Secondary	Pharmacokinetic parameter: AUC (0-infinity) of CK-301		Baseline up to 12 weeks after study completion, an average of 6 months
Secondary	Pharmacokinetic parameter: Cmax of CK-301		Baseline up to 12 weeks after study completion, an average of 6 months
Secondary	Pharmacokinetic parameter: Tmax of CK-301		Baseline up to 12 weeks after study completion, an average of 6 months
Secondary	Pharmacokinetic parameter: T(1/2) of CK-301		Baseline up to 12 weeks after study completion, an average of 6 months
Secondary	Number of subjects with anti-CK-301 antibodies		Baseline up to 12 weeks after study completion, an average of 6 months